<?xml version="1.0" encoding="UTF-8"?>
<p>A CHIKF vaccine in advanced stages of clinical development employs an attenuated measles virus strain as a vector to express the CHIKV structural proteins [
 <xref rid="pntd.0006919.ref044" ref-type="bibr">44</xref>]. In a Phase 1 trial, this vaccine was well tolerated and induced neutralizing antibodies in 44% of volunteers receiving a single low-dose, 92% receiving a medium-dose group, and 90% receiving a high-dose. A booster raised seroconversion to 100%, and immunogenicity was not affected by preexisting anti-measles immunity. This vaccine is now in Phase 2 trials (
 <xref rid="pntd.0006919.t001" ref-type="table">Table 1</xref>).
</p>
